Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients: a randomized controlled study

International Journal of Obesity volume 28, pages 378–383 (2004)Cite this article

Abstract

OBJECTIVE: Sibutramine is an effective appetite suppresser agent, but treatment is often complicated with side effects, including palpitations and hypertension. In this study, we aimed to assess the effect of low-dose cardio-selective beta blocker combination with sibutramine treatment.

METHODS: In total, 57 obese subjects were enrolled in the study and separated into two groups in order to receive sibutramine 10 mg/day plus placebo (group P) or sibutramine 10 mg/day plus metoprolol 25 mg/day (group M). Patients were evaluated in the beginning and at the end of the third month with anthropometric measurements, biochemical analysis, peripheral insulin resistance, and ambulatory 24 h blood pressure monitoring. Side effects were evaluated with a visual analog scale.

RESULTS: During the study period, the drop-out rate was significantly higher in group P compared with group M (55 and 21%, respectively, P=0.014). Palpitations and headache were prominent symptoms in group P. Diastolic blood pressure (78.6±11.6 and 70.6±4.8 mmHg, respectively, P=0.013) and mean heart rate (84.3±6.1 and 75.8±8.4 beats/min, respectively, P=0.003) were significantly higher in group P compared with group M at the end of the third month. Weight loss was similar between the two groups (100.9±11.5 to 91.8±12.8 kg for group P, P<0.0001 and 97.9±13.2 to 88.9±13.8 kg for group M, P<0.0001). We did not find any deleterious effect of metoprolol on metabolic parameters.

CONCLUSION: Addition of low-dose metoprolol to sibutramine therapy increased patient compliance to the treatment, and decreased the frequency and severity of side effects including hypertension and palpitations, without decreasing the drug efficacy or causing significant deleterious changes in metabolic parameters.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Troiano RP, Frongillo EA, Sobal J, Levitsky DA . The relationship between body weight and mortality: a quantitative analysis of combined information from existing studies. Int Obes Relat Metab Disord 1996; 20: 63–75.

    CAS  Google Scholar 

  2. Baird IM . Obesity and insurance risk: the insurance industry's viewpoint. PharmacoEconom Suppl 1994; 5 (1): 62–65.

    Article  CAS  Google Scholar 

  3. McGinnis JM, Foege WH . Actual causes of death in United States. JAMA 1993; 270: 2207–2212.

    Article  CAS  Google Scholar 

  4. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL . Overweight and obesity in the United States: prevalence and trends, 1960–1994. Int J Obes Relat Metab Disord 1998; 22: 39–47.

    Article  CAS  Google Scholar 

  5. Bray GA, Ryan DH, Gordon D . A double blind randomized placebo controlled trial of Sibutramin. Obes Res 1996; 4: 263–270.

    Article  CAS  Google Scholar 

  6. Hansen D, Astrup A, Toubro S, Finer N, Kopelman P, Hilsted J, Rossner S, Saris W, VanGaal L, James W . Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance. Int J Obes Relat Metab Disord 2001; 25 (4): 496–501.

    Article  CAS  Google Scholar 

  7. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, Mendels J, Ryan DH, Schwartz SL, Scheinbaum ML, Seaton TB . Sibutramine produces dose-related weight loss. Obes Res 1999; 7: 189–198.

    Article  CAS  Google Scholar 

  8. Hypertension Prevention Trial Research Group. The Hypertension Prevention Trial: three-year effects of dietary changes on blood pressure. Arch Intern Med 1990; 150: 153–162.

  9. Stevens VJ, Corrigan SA, Obarzanek E, Bernauer E, Cook NR, Hebert P, Mattfeldt-Beman M, Oberman A, Sugars C, Dalcin AT . Weight loss intervention in phase 1 of the trials of hypertension prevention. The TOHP Collaborative Research Group. Arch Intern Med 1993; 153: 849–858.

    Article  CAS  Google Scholar 

  10. McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, Johnson F, Mooradian AD . Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000; 160: 2185–2191.

    Article  CAS  Google Scholar 

  11. Hazenberg BP . Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology 2000; 94 (3): 152–158.

    Article  CAS  Google Scholar 

  12. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E . Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999; 106: 179–184.

    Article  CAS  Google Scholar 

  13. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WH, Van Gaal LF . Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356: 2119–2125.

    Article  CAS  Google Scholar 

  14. Swartz AM, Jeremy Evans M, King GA, Thompson DL . Evaluation of a foot-to-foot bioelectrical impedance analyzer in highly active, moderately active and less active young men. Br J Nutr 2002; 88: 205–210.

    Article  CAS  Google Scholar 

  15. Jebb SA, Cole TJ, Doman D, Mugratroyd PR, Prentice AP . Evaluation of the novel Tanita body fat analyzer to measure body composition by comparison with four-compartment model. Br J Nutr 2000; 83: 115–122.

    Article  CAS  Google Scholar 

  16. Mathews DR, Hosker JP, Rudensky A, Turner RC . Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 401–411.

    Article  Google Scholar 

  17. MacMahon S, Cutler J, Brittain E, Higgins M . Obesity and hypertension: epidemiological and clinical issues. Eur Heart J Suppl 1987; 8/B: 57–70.

    Article  Google Scholar 

  18. Cutler JA . Randomized clinical trials of weight reduction in nonhypertensive persons. Ann Epidemiol 1991; 1: 363–370.

    Article  CAS  Google Scholar 

  19. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S . Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomized trial. Lancet 1998; 351: 1755–1762.

    Article  CAS  Google Scholar 

  20. Stamler J . INTERSALT study findings. Public health and medical care implications. Hypertension 1989; 14: 570–577.

    Article  CAS  Google Scholar 

  21. Hirsch J, Mackintosh RM, Aronne LJ . The effects of drugs used to treat obesity on the autonomic nervous system. Obes Res 2000; 8: 227–233.

    Article  CAS  Google Scholar 

  22. Birkenfeld AL, Schroeder C, Boschmann M, Tank J, Franke G, Luft FC, Biaggioni I, Sharma AM, Jordan J . Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation 2002; 106: 2459–2465.

    Article  CAS  Google Scholar 

  23. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC . Hypothesis: beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 2001; 37: 250–254.

    Article  CAS  Google Scholar 

  24. Jequier E, Tappy L . Regulation of body weight in humans. Physiol Rev 1996; 79: 451–480.

    Article  Google Scholar 

  25. Jackson HC, Bearham MC, Hutchins LJ, Mazurkiewicz SE, Needham AM, Heal DJ . Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol 1997; 121: 1613–1618.

    Article  CAS  Google Scholar 

  26. Connoley IP, Liu YL, Frost I, Reckless IP, Heal DJ, Stock MJ . Thermogenic effects of sibutramine and its metabolites. Br J Pharmacol 1999; 126: 1487–1495.

    Article  CAS  Google Scholar 

  27. Sramek JJ, Leibowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR . Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by adrenergic blocking agents: a placebo controlled double-blind, randomized trial. J Hum Hypertens 2002; 16: 13–19.

    Article  CAS  Google Scholar 

  28. Cuellar GEM, Ruiz AM, Monsalve MCR, Berber A . Six month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. Obes Res 2000; 8: 71–82.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Part of this study was presented at the Ninth International Congress on Obesity in Sao Paulo-Brasília and printed as an abstract in the International Journal of Obesity Related Metabolic Disorder 2002; 26: S151.

Author information

Authors and Affiliations

  1. Department of Endocrinology & Metabolism, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey

    H O Ersoz, K Ukinc, C Erem, A Hacihasanoglu & M Telatar

  2. Department of Cardiology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey

    M Baykan & I Durmus

Authors
  1. H O Ersoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Ukinc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Baykan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Erem
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I Durmus
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Hacihasanoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Telatar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H O Ersoz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ersoz, H., Ukinc, K., Baykan, M. et al. Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients: a randomized controlled study. Int J Obes 28, 378–383 (2004). https://doi.org/10.1038/sj.ijo.0802574

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0802574

Keywords

This article is cited by

Search

Advanced search

Quick links